• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

维格列汀在食蟹猴中引起皮肤效应的血管起源:外周交感神经系统和神经肽Y的病理机制作用

Vascular origin of vildagliptin-induced skin effects in Cynomolgus monkeys: pathomechanistic role of peripheral sympathetic system and neuropeptide Y.

作者信息

Hoffmann Peter, Bentley Phil, Sahota Pritam, Schoenfeld Heidi, Martin Lori, Longo Linda, Spaet Robert, Moulin Pierre, Pantano Serafino, Dubost Valerie, Lapadula Dan, Burkey Bryan, Kaushik Virendar, Zhou Wei, Hayes Michael, Flavahan Nick, Chibout Salah-Dine, Busch Steve

机构信息

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.

出版信息

Toxicol Pathol. 2014 Jun;42(4):684-95. doi: 10.1177/0192623313516828. Epub 2014 Jan 20.

DOI:10.1177/0192623313516828
PMID:24448599
Abstract

The purpose of this article is to characterize skin lesions in cynomolgus monkeys following vildagliptin (dipeptidyl peptidase-4 inhibitor) treatment. Oral vildagliptin administration caused dose-dependent and reversible blister formation, peeling and flaking skin, erosions, ulcerations, scabs, and sores involving the extremities at ≥5 mg/kg/day and necrosis of the tail and the pinnae at ≥80 mg/kg/day after 3 weeks of treatment. At the affected sites, the media and the endothelium of dermal arterioles showed hypertrophy/hyperplasia. Skin lesion formation was prevented by elevating ambient temperature. Vildagliptin treatment also produced an increase in blood pressure and heart rate likely via increased sympathetic tone. Following treatment with vildagliptin at 80 mg/kg/day, the recovery time after lowering the temperature in the feet of monkeys and inducing cold stress was prolonged. Ex vivo investigations showed that small digital arteries from skin biopsies of vildagliptin-treated monkeys exhibited an increase in neuropeptide Y-induced vasoconstriction. This finding correlated with a specific increase in NPY and in NPY1 receptors observed in the skin of vildagliptin-treated monkeys. Present data provide evidence that skin effects in monkeys are of vascular origin and that the effects on the NPY system in combination with increased peripheral sympathetic tone play an important pathomechanistic role in the pathogenesis of cutaneous toxicity.

摘要

本文旨在描述维格列汀(二肽基肽酶-4抑制剂)治疗后的食蟹猴皮肤损伤情况。口服维格列汀导致剂量依赖性且可逆的水疱形成、皮肤脱皮和剥落、糜烂、溃疡、结痂以及在≥5mg/kg/天剂量时累及四肢的疮疡,以及在治疗3周后≥80mg/kg/天剂量时出现的尾巴和耳廓坏死。在受影响部位,真皮小动脉的中膜和内皮显示肥大/增生。通过提高环境温度可预防皮肤损伤形成。维格列汀治疗还可能通过增加交感神经张力导致血压和心率升高。在以80mg/kg/天的剂量用维格列汀治疗后,降低猴子足部温度并诱导冷应激后的恢复时间延长。体外研究表明,取自维格列汀治疗猴子皮肤活检的指动脉对神经肽Y诱导的血管收缩增加。这一发现与在维格列汀治疗猴子的皮肤中观察到的神经肽Y和神经肽Y1受体的特异性增加相关。现有数据提供了证据,表明猴子的皮肤效应源于血管,并且对神经肽Y系统的影响与外周交感神经张力增加相结合在皮肤毒性的发病机制中起重要的病理机制作用。

相似文献

1
Vascular origin of vildagliptin-induced skin effects in Cynomolgus monkeys: pathomechanistic role of peripheral sympathetic system and neuropeptide Y.维格列汀在食蟹猴中引起皮肤效应的血管起源:外周交感神经系统和神经肽Y的病理机制作用
Toxicol Pathol. 2014 Jun;42(4):684-95. doi: 10.1177/0192623313516828. Epub 2014 Jan 20.
2
Acute Toxicity of Vildagliptin.维格列汀的急性毒性
Toxicol Pathol. 2017 Jan;45(1):76-83. doi: 10.1177/0192623316672944. Epub 2016 Oct 17.
3
Dipeptidyl peptidase 4 inhibitor reduces intimal hyperplasia in rabbit autologous jugular vein graft under poor distal runoff.二肽基肽酶4抑制剂可减轻远端血流不佳情况下兔自体颈静脉移植物的内膜增生。
J Vasc Surg. 2016 May;63(5):1360-70. doi: 10.1016/j.jvs.2014.12.048. Epub 2015 Feb 2.
4
Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.伏格列波糖(一种二肽基肽酶-4 抑制剂)对健康志愿者心脏复极和传导影响的全面 QT 研究。
Curr Med Res Opin. 2011 Jul;27(7):1453-63. doi: 10.1185/03007995.2011.585395. Epub 2011 May 24.
5
Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats.二肽基肽酶-4抑制对大鼠盐依赖性高血压发展过程中昼夜血压的影响。
Hypertens Res. 2015 Apr;38(4):237-43. doi: 10.1038/hr.2014.173. Epub 2015 Jan 15.
6
Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited.重新审视二肽基肽酶8和9抑制对啮齿动物的不良影响。
Diabetes Obes Metab. 2008 Nov;10(11):1057-61. doi: 10.1111/j.1463-1326.2008.00860.x. Epub 2008 Apr 17.
7
Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice.二肽基肽酶 IV(DPP-IV)抑制可预防肥胖小鼠脂肪组织纤维化。
Biochim Biophys Acta Gen Subj. 2018 Mar;1862(3):403-413. doi: 10.1016/j.bbagen.2017.11.012. Epub 2017 Dec 22.
8
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.维格列汀是一种新型二肽基肽酶IV抑制剂,在健康受试者中,它与抗高血压药物氨氯地平、缬沙坦和雷米普利不存在药代动力学相互作用。
J Clin Pharmacol. 2008 Jan;48(1):85-95. doi: 10.1177/0091270007307880. Epub 2007 Nov 6.
9
Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.新型二肽基肽酶IV抑制剂维格列汀在健康志愿者中的剂量比例关系及食物对其的影响。
J Clin Pharmacol. 2007 Sep;47(9):1152-8. doi: 10.1177/0091270007304313. Epub 2007 Jul 26.
10
Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.维格列汀可降低 1 型糖尿病患者高血糖时的胰高血糖素水平,并在低血糖时持续抑制胰高血糖素的代偿作用。
J Clin Endocrinol Metab. 2012 Oct;97(10):3799-806. doi: 10.1210/jc.2012-2332. Epub 2012 Aug 1.

引用本文的文献

1
Contactless vital signs monitoring in macaques using a mm-wave FMCW radar.使用毫米波 FMCW 雷达对猕猴进行非接触式生命体征监测。
Sci Rep. 2024 Jun 15;14(1):13863. doi: 10.1038/s41598-024-63994-w.
2
Current Insights Into the Role of Neuropeptide Y in Skin Physiology and Pathology.神经肽Y在皮肤生理与病理中作用的当前见解
Front Endocrinol (Lausanne). 2022 Mar 28;13:838434. doi: 10.3389/fendo.2022.838434. eCollection 2022.
3
International Harmonization of Nomenclature and Diagnostic Criteria (INHAND): Non-proliferative and Proliferative Lesions of the Non-human Primate ().
国际命名与诊断标准协调组织(INHAND):非人灵长类动物的非增殖性和增殖性病变()
J Toxicol Pathol. 2021;34(3 Suppl):1S-182S. doi: 10.1293/tox.34.1S. Epub 2021 Sep 28.
4
Automated video-based heart rate tracking for the anesthetized and behaving monkey.基于视频的麻醉和行为猴子的心率自动跟踪。
Sci Rep. 2020 Oct 21;10(1):17940. doi: 10.1038/s41598-020-74954-5.
5
Association between vildagliptin and risk of angioedema, foot ulcers, skin lesions, hepatic toxicity, and serious infections in patients with type 2 diabetes mellitus: A European multidatabase, noninterventional, postauthorization safety study.维格列汀与2型糖尿病患者血管性水肿、足部溃疡、皮肤病变、肝毒性及严重感染风险之间的关联:一项欧洲多数据库、非干预性、上市后安全性研究。
Endocrinol Diabetes Metab. 2019 Jun 21;2(3):e00084. doi: 10.1002/edm2.84. eCollection 2019 Jul.
6
Using imaging photoplethysmography for heart rate estimation in non-human primates.使用影像光体积描记法估计非人类灵长类动物的心率。
PLoS One. 2018 Aug 31;13(8):e0202581. doi: 10.1371/journal.pone.0202581. eCollection 2018.
7
Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance.维格列汀的临床安全性与耐受性——来自随机试验、观察性研究及上市后监测的见解
Eur Endocrinol. 2017 Aug;13(2):68-72. doi: 10.17925/EE.2017.13.02.68. Epub 2017 Aug 22.
8
Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.二肽基肽酶-4抑制剂的药理学、生理学及作用机制
Endocr Rev. 2014 Dec;35(6):992-1019. doi: 10.1210/er.2014-1035. Epub 2014 Sep 12.
9
The nonglycemic actions of dipeptidyl peptidase-4 inhibitors.二肽基肽酶-4抑制剂的非血糖作用。
Biomed Res Int. 2014;2014:368703. doi: 10.1155/2014/368703. Epub 2014 Jul 21.